Collegium Pharmaceutical, Inc. splits its revenue into 7 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Belbuca at $221.7 million, 28% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
815
|
781
|
631
|
567
|
464
|
277
|
310
|
297
|
280
|
—
|
—
|
| Belbuca |
227
+4.3%
share 27.9%
|
222
+4.9%
share 28.4%
|
211
+16.0%
share 33.5%
|
182
share 32.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Xtampza ER |
190
-5.9%
share 23.3%
|
199
share 25.5%
|
—
|
177
+27.8%
share 31.3%
|
139
+33.8%
share 29.9%
|
104
-19.0%
share 37.5%
|
128
+21.9%
share 41.3%
|
105
+51.4%
share 35.4%
|
69
+143.7%
share 24.7%
|
28
|
—
|
| Jornay Pm |
183
+38.2%
share 22.4%
|
149
+299.7%
share 19.1%
|
37
share 5.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Nucynta IR |
87
-21.4%
share 10.6%
|
115
+14.5%
share 14.8%
|
101
-6.9%
share 16.0%
|
108
-3.5%
share 19.1%
|
112
+9.6%
share 24.2%
|
102
-12.1%
share 36.9%
|
116
-1.2%
share 37.5%
|
118
-9.4%
share 39.7%
|
130
share 46.3%
|
—
|
—
|
| Nucynta ER |
62
-22.0%
share 7.7%
|
81
+6.9%
share 10.4%
|
76
-8.3%
share 12.0%
|
83
+14.1%
share 14.6%
|
72
+2.1%
share 15.6%
|
71
+7.9%
share 25.6%
|
66
-11.2%
share 21.2%
|
74
-8.8%
share 24.9%
|
81
share 28.9%
|
—
|
—
|
| Symproic |
15
-0.6%
share 1.8%
|
14
-4.3%
share 1.9%
|
15
-8.4%
share 2.4%
|
16
+34.5%
share 2.9%
|
12
share 2.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Bema Fentany |
—
|
—
|
—
|
—
|
2
share 0.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COLL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- VA
- Headquarters
- Stoughton, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1267565
- Former names
- COLLEGIUM PHARMACEUTICAL INC (until Mar 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.